Valneva: new marketing authorisation application in chikungu
(CercleFinance.com) - Valneva announces that it has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for its candidate single injection vaccine against chikungunya, VLA1553.
NB: cp yesteday -4.3%
The vaccine company has also been granted an accelerated review of this application by the EMA's Committee for Medicinal Products for Human Use (CHMP), considering the major interest for public health and therapeutic innovation of this candidate vaccine.
Marketing authorisation applications have also been submitted to the US FDA and Health Canada. VLA1553 could therefore become the world's first chikungunya vaccine to meet this unmet medical need.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
NB: cp yesteday -4.3%
The vaccine company has also been granted an accelerated review of this application by the EMA's Committee for Medicinal Products for Human Use (CHMP), considering the major interest for public health and therapeutic innovation of this candidate vaccine.
Marketing authorisation applications have also been submitted to the US FDA and Health Canada. VLA1553 could therefore become the world's first chikungunya vaccine to meet this unmet medical need.
Copyright (c) 2023 CercleFinance.com. All rights reserved.